Savara, Inc. (SVRA)
NASDAQ: SVRA · Delayed Price · USD
1.30
-0.02 (-1.52%)
At close: May 26, 2022 3:59 PM
1.28
-0.02 (-1.54%)
After-hours:May 26, 2022 4:00 PM EDT
Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
The company is headquartered in Austin, Texas.
Savara, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 22 |
| CEO | Robert Neville |
Contact Details
Address: 900 S Capital of Texas Hwy West Lake Hills, Texas 78746-5469 United States | |
| Phone | 512 614 1848 |
| Website | savarapharma.com |
Stock Details
| Ticker Symbol | SVRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001160308 |
Key Executives
| Name | Position |
|---|---|
| Matthew Pauls | Chairman and Chief Executive Officer |
| David L. Lowrance CPA | Chief Financial Officer and Secretary |
| Dr. Badrul A. Chowdhury M.D., Ph.D. | Chief Medical Officer |
| Kate McCabe | Senior Vice President of Legal Affairs |
| Anne Erickson | Senior Vice President and Chief of Staff |
| Dr. Dhaval Desai M.D. | Senior Vice President and Head of Clinical Development |
| Brian Maurer | Head of Clinical Operations |
| Charles LaPree | Senior Vice President of Global Regulatory Affairs and Quality Assurance |
| Dr. Peter Clarke Ph.D. | Executive Vice President of Global Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 11, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| Apr 22, 2022 | 8-K | Current report |
| Apr 19, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 19, 2022 | DEF 14A | Other definitive proxy statements |
| Mar 30, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 30, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Feb 14, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Feb 10, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Jan 13, 2022 | 8-K | Current report |
| View All SEC Filings | ||